中新藥業(600329.SH):擬將使用自有資金進行現金管理的額度調整至4.8億元
格隆匯 9 月 22日丨中新藥業(600329.SH)公佈,公司於2020年4月17日召開2020年第三次董事會,會議審議通過了“公司使用不超過2.8億元人民幣自有資金進行現金管理的議案”。為進一步提高公司資金的使用效率,在安全無風險的基礎上獲取更高的資金收益,公司擬將使用自有資金進行現金管理的額度調整至4.8億元人民幣。
為提高自有資金使用效率,在確保不影響公司資金安全和資金使用的前提下,董事會同意公司根據實際需要,對暫時閒置的自有資金不超過4.8億元(佔公司最近一期經審計淨資產的8.91%)進行現金管理,以增加資金收益,為公司和股東謀取較好的投資回報。現金管理投資產品的期限不得超過本次董事會審議通過之日起12個月,在上述額度範圍內,資金可滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.